A protease inhibitor for the treatment of patients with HIV-1 infection

Formulary

Volumn 34, Issue 7, 1999, Pages 567-577

  Reddy, Prabashni ^a   Ross, Jack ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ASTEMIZOLE; CLARITHROMYCIN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; KETOCONAZOLE; LAMIVUDINE; METHADONE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIFABUTIN; RIFAMPICIN; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; DIARRHEA; DRUG BIOAVAILABILITY; DRUG CONFORMATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TOXICITY; MEDICAL LITERATURE; NEPHROLITHIASIS; PARESTHESIA; PROTEINASE INHIBITION; RASH; TREATMENT OUTCOME; VIRUS LOAD;

EID: 0032781959     PISSN: 1082801X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Flexner C. HIV-protease inhibitors. N Engl J Med 1998;338:1281-91.
2. Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998. JAMA 1998;280:78-86.
3. Decks SG. Issues in salvage therapy. Presented at: 38th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Sept 24-27, 1998; San Diego. Abstract S-29.
4. Data on file. Research Triangle Park, NC: Glaxo Wellcome; March 1999.
5. Livingston DJ, Pazhanisamy S, Porter DJT, et al. Weak binding of VX-478 to human plasma proteins and implications for antihuman immunodeficiency virus therapy. J Infect Dis 1995;172:1238-45.
6. Agenerase package insert. Research Triangle Park, NC: Glaxo Wellcome; April 1999.
7. Adkins JC, Faulds D. Amprenavir. Drugs 1998;55:837-42.
8. St. Clair MH, Millard J, Rooney J, et al. In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents. Antiviral Res 1996;29:53-6.
9. Billelo JA, Billelo PA, Symonds W, et al. Amprenavir (141W940 in combination with 1592U89 is highly synergistic in vitro. Presented at: 38th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Sept 24-27, 1998; San Diego. Abstract I-21.
10. Kaul DR, Cinti SK, Carver PL, et al. HIV protease inhibitors: Advances in therapy and adverse reactions, including metabolic complications. Pharmacotherapy 1999;19:281-98.
11. Nishiyama M, Koishi M, Fujioka M, et al. Phase I clinical trial with a novel protease inhibitor for HIV, KVX-478 in healthy male volunteers. Antiviral Res 1996;30:A35.
12. Zhang XQ, Schooley RT, Gerber JG. The effect of increasing alpha-1 acid glycoprotein (AGP) concentration on the antiretroviral efficiency of HIV protease inhibitors (PI). Presented at: 38th Annual Meeting of the International Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Sept 24-27, 1998; San Diego. Abstract A-42.
13. Decker CJ, Laitinen LM, Bridson GW, et al. Metabolism of amprenavir in liver microsomes: Role of CYP3A4 inhibition for drug interactions. J Pharm Sci 1998;87:803-7.
14. Woolley J, Studenberg S, Boehlert C, et al. Cytochrome p-450 isoenzyme induction, inhibition and metabolism studies with the HIV protease inhibitor, 141W94. Presented at: 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Sept 28-Oct 1, 1997; Toronto. Abstract A-60.
15. Haubrich R. Phase II study of amprenavir, a novel protease inhibitor, in combination with zidovudine/3TC. Presented at: 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 122321.
16. Mellors J, Lederman M, Haas D, et al. Durable activity of Ziagen (abacavir, ABC) combined with protease inhibitors in therapy naive patients. Presented at: Sixth Conference on Retroviruses and Opportunistic Infections; Jan 31-Feb 4, 1999; Chicago. Abstract 625.
17. Bart PA, Rizzardi GP, Gallant S, et al. Combination Ziagen (abacavir, ABC)/Amprenavir (141,APV-USAN) therapy in HIV-1 infected antiretroviral naive subjects with CD4+ counts > 400 copies/μl. Presented at: Sixth Conference on Retroviruses and Opportunistic Infections; Jan 31-Feb 4, 1999; Chicago. Abstract 626.
18. Kost R, Cao Y, Zhang L, et al. Potent, durable combination therapy with abacavir, amprenavir, and AZT/3TC in subjects acutely and chronically infected with HIV-1. Presented at: Sixth Conference on Retroviruses and Opportunistic Infections; Jan 31-Feb 4, 1999; Chicago. Abstract 639.
19. Eron J, Haubrich R, Richman D, et al. Preliminary assessment of 141W94 in combination with other protease inhibitors. Presented at: Sixth Conference on Retroviruses and Opportunistic Infections; Jan 31-Feb 4, 1999; Chicago. Abstract 6.
20. Yogev R, Church J, Flynn P, et al. Pediatric trial of combination therapy including the protease inhibitor amprenavir. Presented at: Sixth Conference on Retroviruses and Opportunistic Infections; Jan 31-Feb 4, 1999. Chicago. Abstract 430.
21. Falloon J, Masur H, Brosgart C, et al. Salvage therapy with abacavir, amprenavir, and efavirenz in subjects with plasma HIV-1 RNA > 500 copies/ml despite protease inhibitor therapy. Presented at: Infectious Diseases Society of America 36th Annual Meeting; Nov 12-15, 1998; Denver. Poster 441.
22. Goodgame J, Stein A, Pottage J, et al. Amprenavir (141W94, APV USAN approved)/ 3TC/AZT is superior to 3TC/AZT in HIV-1 infected antiretroviral therapy-naive subjects. Presented at: 38th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Sept 24-27, 1998; San Diego. Abstract LB-5.
23. Murphy R, Degruttola V, Gulick R, et al. 141W94 with or without zidovudine/3TC in patients with no prior protease inhibitor or 3TC therapy-ACTG 347. Presented at: Fifth Conference on Retroviruses and Opportunistic Infections; Feb 1-5, 1998; Chicago. Abstract 512.
24. Pedneault L, Fetter A, Hanson C, et al. Amprenavir (141W94, APV USAN approved): Review of overall safety profile. Presented at: Sixth Conference on Retroviruses and Opportunistic Infections; Jan 31-Feb 4, 1999; Chicago. Abstract 386.
25. Painter GR, St.Clair MH, Demiranda P, et al. An overview of the preclinical development of the HIV protease inhibitor VX-478 (141W94). Presented at: Second National Conference on Human Retroviruses; Jan 29-Feb 2, 1995; Washington, DC. Abstract LB5.
26. Flexner C. Antiretroviral drug interactions. Presented at: 38th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Sept 24-27, 1998; San Diego. Abstract S-152.
27. Polk RE, Israel DS, Pastor A, et al. Effects of clarithromycin on the pharmacokinetics of amprenavir. Presented at: 38th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Sept 24-27, 1998; San Diego. Abstract A-73.
28. Fiske WD, Benedek IH, Joshi A, et al. Summary of pharmacokinetic drug interaction studies with efavirenz. Presented at: Infectious Diseases Society of America 36th Annual Meeting; Nov 12-15, 1998; Denver. Poster 460.
29. McDowell JA, Sadler BM, Millard, et al. Evaluation of potential pharmacokinetic drug interaction between 141W94 and 1592U89 in HIV+ patients. Presented at: 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Sept 28-Oct 1, 1997; Toronto. Abstract A-62.
30. Kempf DJ, Marsh KC, Kumar G, et al. Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother 1997;41:654-60.
31. Polk RE, Israel DS, Pastor A, et al. Pharmacokinetic interaction between ketoconazole and the HIV protease inhibitor 141W94 after single dose administration to normal volunteers. Presented at: 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Sept 28-Oct 1, 1997; Toronto. Abstract A-61.
32. 1999 Drug Topics Red Book. Montvale, NJ: Medical Economics Co.
33. Sadler BM, Eron J, Wakeford J, et al. Pharmacokinetics of 141W94 and Indinavir (IDV) after single-dose coadministration in HIV-positive volunteers. Presented at: 37th Annual Meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); Sept 28-Oct 1, 1997; Toronto. Abstract A-56.